These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24255895)

  • 1. Vascular response to vasodilator treatment in microalbuminuric diabetic kidney disease.
    Futrakul N; Futrakul P
    World J Nephrol; 2013 Nov; 2(4):125-8. PubMed ID: 24255895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced peritubular capillary flow and renal function can be accomplished in normoalbuminuric type 2 diabetic nephropathy.
    Futrakul N; Kulaputana O; Futrakul P; Chavanakul A; Deekajorndech T
    Ren Fail; 2011; 33(3):312-5. PubMed ID: 21401356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular homeostasis and angiogenesis determine therapeutic effectiveness in type 2 diabetes.
    Futrakul N; Futrakul P
    Int J Vasc Med; 2011; 2011():971524. PubMed ID: 21748023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered vascular homeostasis in type 2 diabetic nephropathy.
    Futrakul N; Butthep P; Futrakul P
    Ren Fail; 2009; 31(3):207-10. PubMed ID: 19288326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review on urine albumin testing for early detection of diabetic complications.
    Newman DJ; Mattock MB; Dawnay AB; Kerry S; McGuire A; Yaqoob M; Hitman GA; Hawke C
    Health Technol Assess; 2005 Aug; 9(30):iii-vi, xiii-163. PubMed ID: 16095545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urgent call for reconsideration of chronic kidney disease.
    Futrakul N; Futrakul P
    World J Nephrol; 2012 Dec; 1(6):155-9. PubMed ID: 24175254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus.
    McKenna K; Thompson C
    Scott Med J; 1997 Aug; 42(4):99-104. PubMed ID: 9507584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of microalbuminuria as an indicator of incipient diabetic nephropathy: therapeutic implications.
    Chiarelli F; Verrotti A; Mohn A; Morgese G
    Ann Med; 1997 Oct; 29(5):439-45. PubMed ID: 9453292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early stage of vascular disease and diabetic kidney disease: an under-recognized entity.
    Futrakul N; Chanakul A; Futrakul P; Deekajorndech T
    Ren Fail; 2015; 37(8):1243-6. PubMed ID: 26365595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships among microalbuminuria, insulin resistance and renal-cardiac complications in insulin dependent and non insulin dependent diabetes.
    Nosadini R; Brocco E
    Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 2():1-7. PubMed ID: 9288531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve shifting paradigms in diabetic renal disease and hypertension.
    Mogensen CE
    Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S2-9. PubMed ID: 18947897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WITHDRAWN: Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria.
    Lovell HG
    Cochrane Database Syst Rev; 2007 Jul; (1):CD002183. PubMed ID: 17636698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria.
    Lovell HG
    Cochrane Database Syst Rev; 2001; (1):CD002183. PubMed ID: 11279757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes.
    Shigihara T; Sato A; Hayashi K; Saruta T
    Hypertens Res; 2000 May; 23(3):219-26. PubMed ID: 10821130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II type 2 receptor-mediated and nitric oxide-dependent renal vasodilator response to compound 21 unmasked by angiotensin-converting enzyme inhibition in spontaneously hypertensive rats in vivo.
    Brouwers S; Smolders I; Massie A; Dupont AG
    Hypertension; 2013 Nov; 62(5):920-6. PubMed ID: 24041944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
    Chan JC; Ko GT; Leung DH; Cheung RC; Cheung MY; So WY; Swaminathan R; Nicholls MG; Critchley JA; Cockram CS
    Kidney Int; 2000 Feb; 57(2):590-600. PubMed ID: 10652036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal microvascular disease predicts renal function in diabetes.
    Futrakul N; Futrakul P
    Ren Fail; 2012; 34(1):126-9. PubMed ID: 22010784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy.
    Imanishi M; Okada N; Konishi Y; Morikawa T; Maeda I; Kitabayashi C; Masada M; Shirahashi N; Wilcox CS; Nishiyama A
    J Renin Angiotensin Aldosterone Syst; 2013 Mar; 14(1):67-73. PubMed ID: 22859713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria.
    Lovell HG
    Cochrane Database Syst Rev; 2000; (2):CD002183. PubMed ID: 10796871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.